3rd Circ. Parses 'Could' And 'Would' In Lipitor Lawsuit

By Carla Baranauckas · September 30, 2025, 11:02 PM EDT

A Third Circuit panel questioned Tuesday whether drug wholesalers and health plans had offered enough evidence that Pfizer Inc. and Ranbaxy Laboratories Ltd. conspired to delay generic competition for the cholesterol...

To view the full article, register now.

Case Information

Case Title

In re: Lipitor Antitrust Litigation

Case Number

24-2184

Court

Appellate - 3rd Circuit

Nature of Suit

3410 Antitrust

Date Filed

July 08, 2024


Case Title

In re: Lipitor Antitrust Litigation

Case Number

24-2185

Court

Appellate - 3rd Circuit

Nature of Suit

3410 Antitrust

Date Filed

July 08, 2024


Case Title

In re: Lipitor Antitrust Litigation

Case Number

24-2189

Court

Appellate - 3rd Circuit

Nature of Suit

3410 Antitrust

Date Filed

July 08, 2024


Case Title

In re: Lipitor Antitrust Litigation, et al

Case Number

24-2194

Court

Appellate - 3rd Circuit

Nature of Suit

3410 Antitrust

Date Filed

July 08, 2024


Case Title

In re: Lipitor Antitrust Litigation

Case Number

24-2202

Court

Appellate - 3rd Circuit

Nature of Suit

3410 Antitrust

Date Filed

July 08, 2024


Case Title

In re: Lipitor Antitrust Litigation

Case Number

24-2203

Court

Appellate - 3rd Circuit

Nature of Suit

3410 Antitrust

Date Filed

July 08, 2024


Case Title

In re: Lipitor Antitrust Litigation

Case Number

24-2256

Court

Appellate - 3rd Circuit

Nature of Suit

3410 Antitrust

Date Filed

July 17, 2024


Case Title

In re: Lipitor Antitrust Litigation

Case Number

24-2257

Court

Appellate - 3rd Circuit

Nature of Suit

3410 Antitrust

Date Filed

July 17, 2024